StreetInsider.com News Articles

Form 6-K Alvotech For: Jun 04

Thu, 04 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260604/26603504.html

Form 6-K Alvotech For: Jun 04

Thu, 04 Jun 2026 09:18:00 -0400

si-local-file:///var/storage/secattach/20260604/26603504.html

Alvotech renews market making deal with Islandsbanki for NASDAQ trading

Mon, 01 Jun 2026 04:41:53 -0400

Alvotech (NASDAQ: ALVO) and Islandsbanki have renewed their market making agreement for ALVO shares trading on Nasdaq Iceland Main Market, according to a company statement.

Under the amended agreement executed May 29, 2026, Islandsbanki will maintain bid and ask quotes with an aggregate market value of at least ISK 8 million before daily trading begins. The bank aims to refresh quotes within 15 minutes of full execution and maintain total outstanding quote values of at least ISK 8 million.

The maximum spread between bid and ask quotes is set at 2.5%, calculated as the volume weighted average of quotes posted by Islandsbanki.

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

Mon, 01 Jun 2026 04:30:00 -0400

REYKJAVIK, ICELAND (June 1, 2026) — Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making agreement. According to the agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price.

The objective of the market-making agreement is to increase trade in Alvotech’s shares, liquidity and transparent price formation.

As a market maker, Islandsbanki will post bid and ask quotes on the Exchange with an aggregate market value of at least ISK 8 million prior

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

Mon, 01 Jun 2026 04:30:00 -0400

The objective of the market-making agreement is to increase trade in Alvotech’s shares, liquidity and transparent price formation.

As a market maker, Islandsbanki will post bid and ask quotes on the Exchange with an aggregate market value of at least ISK 8 million prior

Form 6-K Alvotech For: May 11

Mon, 11 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260511/26465724.html

Form 6-K Alvotech For: May 11

Mon, 11 May 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260511/26465724.html

Alvotech completes FDA inspection at Iceland facility

Mon, 11 May 2026 04:50:23 -0400

Alvotech (NASDAQ: ALVO) announced that the U.S. Food and Drug Administration completed a routine cGMP surveillance inspection of the company's manufacturing facility in Reykjavik, Iceland.

The FDA issued a Form 483 at the conclusion of the inspection on May 8. Alvotech stated the observations can be addressed quickly and do not raise substantial issues with the site or its operations.

The biotechnology company said it remains positioned to resubmit relevant Biologics License Applications in the second quarter once final data have been compiled. The company continues to expect FDA approval for the relevant BLAs during 2026.

Alvotech develops and manufactures biosimilar medicines. The

Alvotech completes FDA inspection at Iceland facility

Mon, 11 May 2026 04:50:23 -0400

Alvotech (NASDAQ: ALVO) announced that the U.S. Food and Drug Administration completed a routine cGMP surveillance inspection of the company's manufacturing facility in Reykjavik, Iceland.

The FDA issued a Form 483 at the conclusion of the inspection on May 8. Alvotech stated the observations can be addressed quickly and do not raise substantial issues with the site or its operations.

Alvotech develops and manufactures biosimilar medicines. The

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

Mon, 11 May 2026 04:30:00 -0400